Wall Street Zen upgraded shares of Ironwood Pharmaceuticals (NASDAQ:IRWD – Free Report) from a buy rating to a strong-buy rating in a research report released on Sunday morning,Wall Street Zen reports.
Several other equities research analysts have also recently commented on the stock. Jefferies Financial Group raised shares of Ironwood Pharmaceuticals to a “hold” rating in a research report on Friday, September 25th. Weiss Ratings raised shares of Ironwood Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. Finally, Zacks Research downgraded shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $6.23.
Get Our Latest Research Report on Ironwood Pharmaceuticals
Ironwood Pharmaceuticals Stock Up 0.4%
NASDAQ:IRWD opened at $4.87 on Friday. The company has a fifty day moving average of $3.99 and a 200 day moving average of $3.96. Ironwood Pharmaceuticals has a 52 week low of $2.95 and a 52 week high of $5.78. The firm has a market capitalization of $806.23 million, a P/E ratio of 5.39 and a beta of 0.25.
Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.32 by $0.04. Ironwood Pharmaceuticals had a net margin of 37.38% and a negative return on equity of 81.40%. The business had revenue of $133.04 million for the quarter, compared to analyst estimates of $119.99 million. As a group, analysts anticipate that Ironwood Pharmaceuticals will post 1.10 EPS for the current year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the company. Principal Financial Group Inc. bought a new position in Ironwood Pharmaceuticals in the first quarter worth approximately $40,000. Lighthouse Investment Partners LLC purchased a new position in shares of Ironwood Pharmaceuticals during the 3rd quarter worth $49,000. Bull Harbor Capital LLC purchased a new stake in shares of Ironwood Pharmaceuticals in the 1st quarter worth $48,000. Ascent Group LLC bought a new position in Ironwood Pharmaceuticals in the 3rd quarter worth $58,000. Finally, Private Wealth Asset Management LLC raised its holdings in Ironwood Pharmaceuticals by 160.5% in the 3rd quarter. Private Wealth Asset Management LLC now owns 15,632 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 9,632 shares during the period.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals is a biotechnology company focused on developing and commercializing treatments for gastrointestinal diseases. Founded in 1998, the company is headquartered in Boston, Massachusetts. Its principal product is LINZESS (linaclotide), a prescription medicine for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation. Ironwood and AbbVie collaborate on the product’s U.S. commercialization, while licensing partners make linaclotide available in other markets under regional brand names.
Read More
- Five stocks we like better than Ironwood Pharmaceuticals
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
